Skip to main content

Table 3 Pharmacokinetic values

From: Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer

 

Unit

0.2 g/kg(n = 3)

0.4 g/kg(n = 3)

0.6 g/kg(n = 3)

0.8 g/kg(n = 3)

1 g/kg(n = 2)

1.2 g/kg(n = 3)

1.5 g/kg(n = 3)

D1

Cmax (mmol/l)

4.2 ± 3.9

5.1 ± 1.1

7.4 ± 1.2

12.1 ± 5.7

14.0 ± 3.9

16.4 ± 2.5

17.4 ± 7.2

t1/2(h)

3.1 ± 1.2

1.8 ± 0.6

2.0 ± 0.2

1.9 ± 0.05

1.5 ± 0.2

1.4 ± 0.09

1.97 ± 0.8

AUC (mmol/l *h)

21.0 ± 18.0

22.5 ± 8.8

31.5 ± 3.0

49.0 ± 15.8

55.3 ± 2.3

73.3 ± 12.3

82.3 ± 43.3

Vz (ml)

15.3 ± 5.6

13.6 ± 1.7

14.2 ± 3.8

14.2 ± 2.4

12.7 ± 1.6

11.5 ± 1.3

14.9 ± 4.0

Cl (ml/h)

4.1 ± 2.5

5.8 ± 2.9

4.9 ± 1.4

5.1 ± 1.0

6.0 ± 0.03

5.5 ± 0.4

5.5 ± 1.7

D3

Cmax (mmol/l)

3.5 ± 1.7

3.7 ± 0.9

7.2 ± 1.1

11.2 ± 3.3

9.5 ± 3.0

16.5 ± 1.5

17.8 ± 5.5

t1/2(h)

1.9 ± 0.8

2.4 ± 0.9

1.7 ± 0.4

1.6 ± 0.1

1.5 ± 0.2

1.5 ± 0.06

1.98 ± 0.6

AUC (mmol/l *h)

14.9 ± 7.4

19.0 ± 7.5

34.1 ± 3.9

54.8 ± 16.1

35.4 ± 15.8

65.5 ± 8.0

89.5 ± 52.4

Vz (ml)

12.2 ± 7.6

21.4 ± 3.2

10.6 ± 3.6

10.9 ± 2.7

22.6 ± 7.7

13.3 ± 3.4

14.2 ± 3.6

Cl (ml/h)

4.4 ± 1.8

6.9 ± 3.5

4.4 ± 0.6

4.6 ± 1.0

10.5 ± 5.0

6.2 ± 1.4

5.3 ± 2.1